Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Hematology | Oncology | Urology | Journal

Back to Journal Articles

Prostate Cancer Linked to Thromboembolism

Last Updated: April 14, 2010.

 

Treated, untreated patients have increased risk of deep-venous thrombosis, pulmonary embolism

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Prostate cancer patients -- especially those receiving endocrine therapy -- have an increased risk of thromboembolism, according to a study published online April 14 in The Lancet Oncology.

WEDNESDAY, April 14 (HealthDay News) -- Prostate cancer patients -- especially those receiving endocrine therapy -- have an increased risk of thromboembolism, according to a study published online April 14 in The Lancet Oncology.

Mieke Van Hemelrijck, of King's College London, and colleagues analyzed data from PCBaSe Sweden, a database based on the National Prostate Cancer Register, which covers over 96 percent of prostate cancer cases in Sweden. The data involved 30,642 men who received primary endocrine therapy, 26,432 who received curative treatment, and 19,526 who were placed on surveillance between Jan. 1, 1997, and Dec. 31, 2007.

During the study period, 1,881 patients developed a thromboembolic disease. The researchers found that men receiving endocrine therapy had an increased risk for deep-venous thrombosis and pulmonary embolism (standardized incidence ratios [SIRs], 2.48 and 1.95, respectively) but not for arterial embolism. They observed similar risks for deep-venous thrombosis and pulmonary embolism in men who received curative treatment (SIRs, 1.73 and 2.03, respectively) and in men who were placed on surveillance (SIRs, 1.27 and 1.57, respectively).

"Our results indicate that prostate cancer itself, prostate cancer treatments, and selection mechanisms all contribute to increased risk of thromboembolic disease," the authors conclude. "Thromboembolic disease should be a concern when managing patients with prostate cancer."

One co-author has served on an Astra Zeneca committee. Another co-author received consulting fees from Ferring Pharmaceuticals, which markets a gonadotropin releasing hormone agonist.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2010 HealthDay. All rights reserved.


Previous: Mothers Influence Daughters' Uptake of HPV Vaccine Next: AAN: New Gene Associated With Alzheimer's Disease

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.